The History of MDMA as an Underground Drug in the United States, 1960-1979
This review (2015) focuses on the history of MDMA as an underground drug in the 1960s and 1970s in the United States. It highlights the murky status of its initial synthesis and the significant role of the chemist Alexander T. Shulgin who shared spread the protocol of its synthesis across the mid-west and popularized MDMA on a national scale to an estimated use of 30,000 pills per month by 1983 until it was banned in 1985.
Authors
- Thomas Passie
Published
Abstract
MDMA (3,4-methylenedioxy-methylamphetamine, a.k.a. “ecstasy”) was first synthesized in 1912 and resynthesized more than once for pharmaceutical reasons before it became a popular recreational drug. Partially based on previously overlooked U.S. government documentation, this article reconstructs the early history of MDMA as a recreational drug in the U.S. from 1960 to 1979. According to the literature, MDMA was introduced as a street drug at the end of the 1960s. The first forensic detection of MDMA “on the street” was reported in 1970 in Chicago. It appears that MDMA was first synthesized by underground chemists in search of “legal alternatives” for the closely related and highly sought-after drug MDA, which was scheduled under the Controlled Substances Act (CSA) in 1970. Until 1974, nearly all MDMA street samples seized came from the U.S. Midwest, the first “hot region” of MDMA use. In Canada, MDMA was first detected in 1974 and scheduled in 1976. From 1975 to 1979, MDMA was found in street samples in more than 10 U.S. states, the West Coast becoming the major “hot region” of MDMA use. Recreational use of MDMA spread across the U.S. in the early 1980s, and in 1985 it was scheduled under the CSA.
Research Summary of 'The History of MDMA as an Underground Drug in the United States, 1960-1979'
Introduction
By the 1990s MDMA (3,4-methylenedioxy-methylamphetamine, “ecstasy”) had become a major recreational drug worldwide, but its early history as an underground substance in the United States is incompletely documented. Earlier work shows MDMA was synthesised as early as 1912 and resynthesised for pharmaceutical research, while animal testing by the U.S. Army in the 1950s remained largely unpublished until declassification. The chemically related amphetamine MDA had already circulated as a recreational and psychotherapeutic agent in the 1950s–1960s and was scheduled in 1970, creating a context in which altered analogues such as MDMA could be produced as “legal alternatives.” Passie and colleagues set out to reconstruct the emergence and spread of MDMA as an underground recreational drug in the U.S. between about 1960 and 1979. Drawing on previously overlooked sources — notably a 1984 DEA internal document recommending Schedule I control — together with published literature, forensic laboratory reports, seizure records, conference proceedings and laboratory notebooks (notably those of Alexander Shulgin), the study maps forensic detections, clandestine production, distribution patterns and early clinical/perceptual characterisations of MDMA during that period. The paper focuses on the 1960s and 1970s and does not attempt an exhaustive account of developments after 1980, although brief remarks on later scheduling are provided in the summary.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typemeta
- Journal
- Compound
- Author
- APA Citation
Passie, T., & Benzenhöfer, U. (2016). The History of MDMA as an Underground Drug in the United States, 1960-1979. Journal of Psychoactive Drugs, 48(2), 67-75. https://doi.org/10.1080/02791072.2015.1128580
References (2)
Papers cited by this study that are also in Blossom
Benzenhöfer, U., Passie, T. · Addiction (2010)
Nichols, D. E. · Journal of Psychoactive Drugs (1986)
Cited By (6)
Papers in Blossom that reference this study
Ramaekers, J. G., Kuypers, K. P. C., Vollenweider, F. X. · Molecular Psychiatry (2026)
Green, W. M., Raut, S. B., James, F. L. J. et al. · MedRvix (2023)
Traynor, J. M., Roberts, D. E., Ross, S. et al. · Focus (2022)
Sessa, B., Aday, J. S., Curran, H. V. et al. · Journal of Psychopharmacology (2021)
Wagner, A. C., Mithoefer, M. C., Mithoefer, A. T. et al. · Journal of Psychoactive Drugs (2019)
Passie, T., Brandt, S. D. · New Psychoactive Substances (2018)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.